Blog

This is tagline here

Begbroke Science Park > News and Press > Oxford Medical Diagnostics adds Prof Graham Richards to Science Advisory Panel
Please set your featured image

Oxford Medical Diagnostics adds Prof Graham Richards to Science Advisory Panel

Oxford Medical Diagnostics, a developer of advanced diagnostic technology has announced that Professor Graham Richards is joining the company’s Science Advisory Panel.

Professor Richards, head of the Centre for Computational Drug Discovery at Oxford University, brings his considerable expertise in life sciences. He has also contributed to the success of a number of technology-based start-up companies and will be able to advise the company on its development strategy.

“Graham Richards boosts the scientific excellence in the Oxford Medical Diagnostics team and will provide valuable input on our development strategy,” said Oxford Medical Diagnostics CEO, Tony Marchington. “Our Science Advisory Panel includes leading international scientists and a wide range of experience in the science and technology field.”

Professor Richards was a co-founder of one of Oxford University’s most successful spin-offs, along with Marchington. The company, Oxford Molecular Group plc, reached a FTSE 250 valuation of £475 million. Professor Richards is one of the leading computational chemists in the UK, with over 300 publications. He served as Chairman of the Department of Chemistry at Oxford University from 1997 to 2007. He is head of the Centre for Computational Drug Discovery at Oxford.

Throughout his career, Professor Richards has been involved in the commercialization of technologies. In 2001, he founded InhibOx Ltd. He was a director of ISIS Innovation Ltd, the University of Oxford’s technology transfer company and was involved for several years with the Wellcome Trust in a similar capacity. He is also a main board director (formerly chairman) of IP Group plc, the listed intellectual property commercialization company.

Oxford Medical Diagnostics Ltd is developing technology that makes it possible to provide rapid, accurate and low-cost diagnosis and monitoring of disease and metabolic functions. Its initial objective is to bring to market a non-invasive point-of-care diagnostic instrument to detect diabetes types 1 and 2 by detection of acetone in the breath.



For more information please click to visit: www.mtbeurope.info/news/2011/1102008.htm

Ben Roeves